Skip to content

We have completed our Covid-19 Phase 2 clinical trial enrollment.

HOME
ABOUT US
OUR SCIENCE
OUR PLATFORM
NEWS/EVENTS
PUBLICATIONS
CONTACT

Menu

HOME
ABOUT US
OUR SCIENCE
OUR PLATFORM
NEWS/EVENTS
PUBLICATIONS
CONTACT

News/Events

Exciting news about plasma gelsolin therapy and BioAegis Therapeutics discoveries on infectious, inflammatory and degenerative diseases.

News

July 1, 2015: BioAegis Therapeutics Collaboration with Harvard School of Public Health Discovers Plasma Gelsolin Boosts the Immune Response to Pathogens

April 15, 2015: BioAegis Therapeutics Completes Initial $8 Million Convertible Note: Round Oversubscribed

December, 2014: BioAegis Establishes Collaboration with Vanderbilt and Northwestern to Measure Plasma Gelsolin Levels in Community-Acquired Pneumonia Patients

December, 2014: Plasma Gelsolin Broad Infectious Disease Patents Granted in Europe, Canada, Hong Kong and Australia

December 3, 2014: BioAegis Therapeutics Closes Successful $8MM Convertible Note Round

December 3, 2014: Plasma Gelsolin Patent for Therapeutic Use in Renal Failure Granted in Europe

November 10, 2014: BioAegis and the National Institute of Allergy and Infectious Diseases (NIAID) Enter into Research Collaboration

November 10, 2014: BioAegis Therapeutics Seeks Advice from MHRA and MPA in Anticipation of European Phase 2 Clinical Studies

November 28, 2013: BioAegis Therapeutics Completes Engineering Run of High-Yield Recombinant Plasma Gelsolin

November 26, 2013: BioAegis Therapeutics Engages Debra Barngrover to Oversee Recombinant Manufacturing of Plasma Gelsolin

July 28, 2013: FDA Transfers Orphan Drug Designation for Cystic Fibrosis and Bronchiectasis to BioAegis Therapeutics

July 26, 2013: Plasma Gelsolin Inflammation Patent Granted in Japan, Further Expanding Coverage in Asia

Page1 … Page3 Page4 Page5 Page6

Awards

Clinical Trials Arena Award - Best COVID19 Response

Events

October 6-7, 2020: BioNJ’s 10th Annual BioPartnering Conference

August 20, 2020: WIB-Metro New York – Biotech Leadership in the time of COVID-19: Impact, Opportunity, and Resilience

Tweets by BioAegis

Stay informed of our latest discoveries and news.

EMAIL

COMPANY DETAILS

LOCATION:
BioAegis Therapeutics
North Brunswick, NJ

MEDIA INQUIRIES:
Contact: Christine Lagana
clagana@bioaegistx.com

INVESTOR INQUIRIES:
Contact: Steven Cordovano
scordovano@bioaegistx.com

FOLLOW US

JOIN OUR TEAM

©2020 BioAegis® Therapeutics Inc. | Privacy Policy | Terms of Use